A1c 7.6% in a 79-Year-Old Who Wants It Lower
Mrs. K is a 79-year-old widow with 14 years of type 2 diabetes who lives alone. A1c 7.6%; eGFR 42 mL/min/1.73 m2 and stable, creatinine 1.3 mg/dL; weight 62 kg. Medications: metformin 1000 mg twice daily, glyburide 10 mg daily, lisinopril, atorvastatin. In the last 6 weeks she has had two documented hypoglycemia episodes (54 and 48 mg/dL); the second caused a nighttime fall with bruising but no fracture. She has no retinopathy and no ASCVD, and she manages her own medications and finances. She insists, 'My sugar has to be under 7, that's what I was always told,' and asks you to increase her medications so she can 'get there.'
1. State her individualized glycemic target and defend it against her request for intensification.
Read the worked answer
Target: A1c approximately 7.5-8.0%, with an explicit priority on avoiding glucose below about 70 mg/dL. Her current 7.6% is already at goal.
Reasoning -- the goal is individualized, not universal:
- An A1c below 7% is appropriate for many nonpregnant adults with long life expectancy, no significant hypoglycemia, and few comorbidities.
- A less stringent goal (below 8%) is appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced complications, extensive comorbidity, or functional and cognitive impairment.
- She has hypoglycemia with injury on two occasions plus CKD stage 3b, which prolongs sulfonylurea action. That combination places her squarely in the less-stringent group.
The argument to make to her: the benefit of tight control accrues over 8-10 years through microvascular prevention, and she has no retinopathy after 14 years. The harm of one more hypoglycemic fall -- hip fracture, subdural hematoma, loss of independence -- can occur tonight. Her A1c of 7.6% is not a failure; it is the target. Frame the change as reaching her goal, not abandoning it, and note that lowering A1c further would not add benefit she can collect.
Also reassess function and goals of care so the target is documented and travels with her across settings.
2. Which medication changes do you make today, and how does her eGFR drive each one?
Read the worked answer
Stop glyburide. It is a long-acting sulfonylurea whose active metabolites accumulate in CKD, producing prolonged hypoglycemia -- the exact mechanism of her two episodes and her fall. It is flagged as potentially inappropriate in older adults for precisely this reason. Stopping it is the highest-yield intervention in the visit, and it addresses the harm she has already experienced rather than a number on a lab report.
Reduce metformin. Guidance permits continuing metformin at eGFR 30-45 but not initiating it, with the total daily dose commonly capped at 1000 mg, and it is contraindicated below 30. She is on 2000 mg/day -- roughly double what is appropriate for her kidney function. Reduce to 500 mg twice daily. Teach sick-day rules: hold during vomiting, diarrhea, dehydration, or before iodinated contrast, and resume when eating and hydrated.
If A1c rises above 8% after stopping glyburide, add an agent with low hypoglycemia risk. A DPP-4 inhibitor such as linagliptin requires no renal dose adjustment and is a reasonable choice. A GLP-1 receptor agonist is more potent but causes weight loss and appetite suppression, which may be undesirable in a 62-kg frail older woman. An SGLT2 inhibitor would be cardiorenal guideline-concordant but warrants caution for volume depletion and falls risk in a patient who is already falling -- a genuine tradeoff rather than a clear win.
Bottom line: today's visit is a de-escalation visit, and the correct response to 'increase my medications' is a clear explanation of why that would harm her.
3. What monitoring and safety plan do you put in place, and what else should be on your differential for these hypoglycemia episodes?
Read the worked answer
Monitoring:
- A1c in 3 months until stable, then every 6 months.
- eGFR every 3 months given stage 3b and metformin.
- Ask specifically about hypoglycemia symptoms at every visit; consider a continuous glucose monitor if available, since her lows have been nocturnal and she lives alone -- a monitor also gives her visible feedback that replaces a number she has anchored to.
- Vitamin B12 periodically with long-term metformin.
Differential beyond the obvious: I would not attribute both episodes solely to glyburide without checking for missed meals or erratic intake, CKD progression, new interacting medications (including over-the-counter products), alcohol use, and whether she is taking the glyburide more than once daily by mistake. Ask to see her pill bottles -- self-management of a complex regimen while living alone is a real risk factor.
Safety counseling: symptoms and treatment of hypoglycemia (15 g fast-acting carbohydrate, recheck in 15 minutes), keeping a glucose source at the bedside, and driving precautions. After stopping the sulfonylurea she is no longer on a hypoglycemia-causing agent, so a glucagon prescription is not strictly indicated -- but if any hypoglycemia-causing agent is later added, it becomes part of the plan. Finally, document her functional and cognitive status: a fall at night in a woman living alone is a geriatric syndrome question as much as a diabetes question, and the plan should include a home safety and gait review.